HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports.

Abstract
In previous investigations we found an increase of D2 dopamine receptors in the striatum of patients with nocturnal myoclonus syndrome (NMS) after treatment with dopamimetics. Under the hypothesis, that, according to animal experiments, the glutamatergic system could be involved in this atypical dopaminergic up-regulation in NMS. The glutamate release inhibitor lamotrigine was tested in up to now two NMS patients. The results and the success of this approach and its implications are discussed.
AuthorsJ Staedt, G Stoppe, H Riemann, G Hajak, E Rüther, P Riederer
JournalJournal of neural transmission (Vienna, Austria : 1996) (J Neural Transm (Vienna)) Vol. 103 Issue 3 Pg. 355-61 ( 1996) ISSN: 0300-9564 [Print] Austria
PMID8739847 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anticonvulsants
  • Triazines
  • Glutamic Acid
  • Lamotrigine
Topics
  • Anticonvulsants (therapeutic use)
  • Glutamic Acid (metabolism)
  • Humans
  • Lamotrigine
  • Male
  • Middle Aged
  • Myoclonus (drug therapy)
  • Polysomnography
  • Sleep Wake Disorders (drug therapy)
  • Triazines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: